Article
Oncology
Nicolas Destefanis, Valentina Fiano, Lorenzo Milani, Paolo Vasapolli, Michelangelo Fiorentino, Francesca Giunchi, Luca Lianas, Mauro Del Rio, Francesca Frexia, Luca Pireddu, Luca Molinaro, Paola Cassoni, Mauro Giulio Papotti, Paolo Gontero, Giorgio Calleris, Marco Oderda, Umberto Ricardi, Giuseppe Carlo Iorio, Piero Fariselli, Elena Isaevska, Olof Akre, Renata Zelic, Andreas Pettersson, Daniela Zugna, Lorenzo Richiardi
Summary: Introduction Prostate cancer (PCa) is the most common tumor among men in Europe, and this study presents a new Italian cohort called the Turin Prostate Cancer Prognostication (TPCP) cohort, aiming to improve the current prognostication models for PCa. The cohort consists of non-metastatic patients with PCa who underwent a positive biopsy between 2008 and 2013 in Turin, Italy. The study includes various clinical variables, along with histopathologic information, tumor DNA methylation, and features extracted from digitized slide images. The primary outcome is the occurrence of metastasis, while death from PCa and overall mortality are the secondary outcomes. The cohort provides valuable resources for updating and developing new prognostic models for PCa in Italy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Alicja Kmiecik, Katarzyna Ratajczak-Wielgomas, Jedrzej Grzegrzolka, Hanna Romanowicz, Beata Smolarz, Piotr Dziegiel
Summary: The expression of NUCB2/NESF-1 has been found to be linked to tumor development in breast cancer. Higher expression of NUCB2/NESF-1 is associated with longer patient survival, indicating its potential role in malignant transformation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biology
Jialin Meng, Yu Guan, Bijun Wang, Lei Chen, Junyi Chen, Meng Zhang, Chaozhao Liang
Summary: In this study, we established and validated an eleven-consensus-gene classifier for prostate cancer patients, which provides valuable information for prognosis assessment and may improve the current staging system. SRD5A2 inhibits cell proliferation, while ITGA11 promotes cell migration and invasion, possibly through the PI3K/AKT signaling pathway.
COMMUNICATIONS BIOLOGY
(2022)
Article
Oncology
Jerry C. F. Ching, Saikit Lam, Cody C. H. Lam, Angie O. Y. Lui, Joanne C. K. Kwong, Anson Y. H. Lo, Jason W. H. Chan, Jing Cai, W. S. Leung, Shara W. Y. Lee
Summary: The study aimed to investigate the prognostic value of pre-treatment planning CT-based radiomic features and clinical attributes to predict 5-year progression-free survival (PFS) in high-risk prostate cancer patients following prostate-only radiotherapy (PORT). The results showed that the combined model of radiomic and clinical features provided superior prognostication for 5-year PFS in this patient population.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Caterina Gabriele, Licia E. Prestagiacomo, Giovanni Cuda, Marco Gaspari
Summary: This review highlights the association between aberrant glycosylation and prostate cancer, focusing on the application of mass spectrometry in glycoprotein analysis. The glycoforms of prostate specific antigen and the insights provided by mass spectrometric analysis are discussed, shedding light on the mechanisms linking abnormal glycosylation to cancer progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Urology & Nephrology
Matthew J. Roberts, Tobias Maurer, Marlon Perera, Matthias Eiber, Thomas A. Hope, Piet Ost, Shankar Siva, Michael S. Hofman, Declan G. Murphy, Louise Emmett, Wolfgang P. Fendler
Summary: The use of PSMA-directed applications in prostate cancer management has rapidly evolved, providing new treatment pathways and insights into cancer biology. However, the prognostic implications of PSMA-PET have not been systematically studied yet, and further research is needed to determine its impact on oncological outcomes. Current data suggest an association between high PSMA expression and traditional prognostic factors and survival outcomes. However, PSMA-PET has poor sensitivity in detecting all metastases.
NATURE REVIEWS UROLOGY
(2022)
Article
Oncology
Kari S. Wagner-Larsen, Erlend Hodneland, Kristine E. Fasmer, Njal Lura, Kathrine Woie, Bjorn I. Bertelsen, Oyvind Salvesen, Mari K. Halle, Noeska Smit, Camilla Krakstad, Ingfrid S. Haldorsen
Summary: This study confirmed that MRI-based radiomic signatures can predict disease-specific survival in cervical cancer patients and provide added value in guiding tailored treatment strategies.
Article
Endocrinology & Metabolism
Samuel M. M. Cohen, Julia E. E. Noel, Michael Baroody, Lisa A. A. Orloff
Summary: According to a retrospective chart review, preoperative ultrasound can predict regional metastases in papillary thyroid microcarcinoma to some extent. The size of the tumor, distance to the thyroid capsule or trachea, tumor contour, and presence of autoimmune thyroiditis are not correlated with regional metastasis. Nodules in the superior or midpole are associated with central or lateral neck metastases, while nodules in the isthmus or inferior pole are only associated with central neck metastases. Therefore, active surveillance can be considered for patients with papillary thyroid microcarcinoma adjacent to the thyroid capsule.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Biochemical Research Methods
Cristiano Gutta, Christoph Morhard, Markus Rehm
Summary: Prognostic tests based on limited gene expression profiles are only approved for specific clinical features. Deep learning algorithms can potentially stratify patients based on full transcriptome data, but the high number of variables in omics datasets hinders the development of robust classifiers. In this study, a classifier based on a data augmentation pipeline was proposed, which outperformed established biomarkers in stratifying breast cancer patients. Importantly, the classifier performed well across independent and merged transcriptome datasets, improving overall patient stratification.
PLOS COMPUTATIONAL BIOLOGY
(2023)
Article
Mathematical & Computational Biology
Zarif L. Azher, Anish Suvarna, Ji-Qing Chen, Ze Zhang, Brock C. Christensen, Lucas A. Salas, Louis J. Vaickus, Joshua J. Levy
Summary: This study develops an interpretable multimodal modeling framework that combines DNA methylation, gene expression, and histopathology data. By comparing different pretraining strategies, the study demonstrates the importance of pretraining strategies in obtaining accurate prognostication models and emphasizes the significant role of the tumor microenvironment in disease progression.
Review
Cell Biology
James G. Kench, Mahul B. Amin, Daniel M. Berney, Eva M. Comperat, Ian A. Cree, Anthony J. Gill, Arndt Hartmann, Santosh Menon, Holger Moch, George J. Netto, Maria R. Raspollini, Mark A. Rubin, Puay Hoon Tan, Toyonori Tsuzuki, Samra Turjalic, Theo H. van Der Kwast, Ming Zhou, John R. Srigley
Summary: The fifth edition of the WHO Classification of Tumours of the Urinary and Male Genital Systems provides updates on the classification and prognosis assessment of prostatic carcinoma, including recognizing PIN-like carcinoma as a subtype of acinar adenocarcinoma, renaming basal cell carcinoma as adenoid cystic (basal cell) cell carcinoma, discussing grading issues in acinar adenocarcinoma, and providing more detailed coverage of intraductal carcinoma of prostate.
Article
Cell Biology
Zhengquan Wu, Bernd Uhl, Olivier Gires, Christoph A. Reichel
Summary: The study found that senescence of tumor endothelial cells is associated with tumor growth and metastasis. A transcriptomic signature related to endothelial senescence was established using RNA sequencing data, and machine learning algorithms were used to construct survival prognostication and immunotherapy response prediction models for tumor endothelial cells.
JOURNAL OF BIOMEDICAL SCIENCE
(2023)
Article
Biochemistry & Molecular Biology
Anca Gabriela Pavel, Danae Stambouli, Gabriela Anton, Ismail Gener, Adrian Preda, Catalin Baston, Constantin Gingu
Summary: This study aimed to determine the cumulative association between four common SNPs and overall prostate cancer risk. The results showed that the rs4054823 polymorphism was significantly associated with prostate cancer risk, and the heterozygous genotype of the rs2735839 polymorphism was more common in the benign prostate hyperplasia group. Logistic regression analysis revealed that carriers of at least one risk allele copy in each particular region had a cumulative odd ratio of 1.42 times.
Article
Medicine, General & Internal
Marie Obro Fosbol, Jann Mortensen, Peter Meidahl Petersen, Annika Loft, Jacob Madsen, Andreas Kjaer
Summary: This Phase II study aimed to investigate the potential of uPAR PET in assessing response and prognosis in patients receiving (RaCl2)-Ra-223 therapy. The baseline SUVmax was associated with overall survival (OS), while it was found to be a significant predictor of symptomatic skeletal events (SSE).
Article
Oncology
Adam G. Sowalsky, Ines Figueiredo, Rosina T. Lis, Ilsa Coleman, Bora Gurel, Denisa Bogdan, Wei Yuan, Joshua W. Russo, John R. Bright, Nichelle C. Whitlock, Shana Y. Trostel, Anson T. Ku, Radhika A. Patel, Lawrence D. True, Jonathan Welti, Juan M. Jimenez-Vacas, Daniel Nava Rodrigues, Ruth Riisnaes, Antje Neeb, Cynthia T. Sprenger, Amanda Swain, Scott Wilkinson, Fatima Karzai, William L. Dahut, Steven P. Balk, Eva Corey, Peter S. Nelson, Michael C. Haffner, Stephen R. Plymate, Johann S. de Bono, Adam Sharp
Summary: This study demonstrates that further analytical validation and clinical qualification are required before AR-V7 can be considered for clinical use in CSPC as a predictive biomarker.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Martin K. Bakht, John J. Hayward, Farsheed Shahbazi-Raz, Magdalena Skubal, Ryo Tamura, Keith F. Stringer, Daniel Meister, Varadha Balaji Venkadakrishnan, Hui Xue, Adam Pillon, Mathew Stover, Adam Tronchin, Bre-Anne Fifield, Lavleen Mader, Sheng-Yu Ku, Gi Jeong Cheon, Keon Wook Kang, Yuzhuo Wang, Xuesen Dong, Himisha Beltran, Jan Grimm, Lisa A. Porter, John F. Trant
Summary: PSMA is highly overexpressed in most prostate cancers, but effectively absent from certain high-mortality, treatment-resistant subsets such as NEPC. However, GUL-based PSMA tracers still have the potential to identify NEPC metastatic tumors and may bind unknown proteins associated with PSMA-suppressed cancers. We identified the up-regulation of NAALADaseL and mGluRs in PSMA-suppressed prostate cancers, which inversely correlate with PSMA expression and are associated with GUL-based radiotracer uptake. NAALADaseL and mGluR expression also correlates with a unique cell cycle signature.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Pharmacology & Pharmacy
Milad Ashrafizaden, Navid Rabiee, Alan Prem Kumar, Gautam Sethi, Ali Zarrabi, Yuzhuo Wang
Summary: Long noncoding RNAs (lncRNAs) play a role in gene regulation in pancreatic cancer cells, affecting apoptosis, autophagy, proliferation, metastasis, and drug resistance.
DRUG DISCOVERY TODAY
(2022)
Review
Oncology
Milad Ashrafizadeh, Mahshid Deldar Abad Paskeh, Sepideh Mirzaei, Mohammad Hossein Gholami, Ali Zarrabi, Farid Hashemi, Kiavash Hushmandi, Mehrdad Hashemi, Noushin Nabavi, Francesco Crea, Jun Ren, Daniel J. Klionsky, Alan Prem Kumar, Yuzhuo Wang
Summary: This review discusses the role and regulatory mechanisms of autophagy in prostate cancer. Autophagy can impact cancer cell proliferation, survival, and metastasis, as well as the response to therapy. Targeting autophagic genes and utilizing nanotherapeutics show promise in improving patient prognosis.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Correction
Oncology
Sepideh Mirzaei, Mohammad Hossein Gholami, Kiavash Hushmandi, Farid Hashemi, Amirhossein Zabolian, Israel Canadas, Ali Zarrabi, Noushin Nabavi, Amir Reza Aref, Francesco Crea, Yuzhuo Wang, Milad Ashrafizadeh, Alan Prem Kumar
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Sepideh Mirzaei, Mohammad Hossein Gholami, Kiavash Hushmandi, Farid Hshemi, Amirhossein Zabolian, Israel Canadas, Ali Zarrabi, Noushin Nabavi, Amir Reza Aref, Francesco Crea, Yuzhuo Wang, Milad Ashrafizadeh, Alan Prem Kumar
Summary: Non-coding RNAs play significant roles in cancer progression by regulating the expression of enhancer of zeste homolog 2 (EZH2). Different types of ncRNAs, including miRNAs, lncRNAs, and CircRNAs, modulate EZH2 expression through various mechanisms, affecting downstream signaling pathways and therapy response. These mechanisms have important implications for cancer research and treatment.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Cell Biology
Nelson K. Y. Wong, Xin Dong, Yen-Yi Lin, Hui Xue, Rebecca Wu, Dong Lin, Colin Collins, Yuzhuo Wang
Summary: Androgen deprivation therapy is the standard treatment for advanced prostate cancer, but most patients eventually relapse. The study of the dormant phase of prostate cancer progression is hindered by limited clinical tissue and preclinical models. This study uses unique patient-derived xenograft models to investigate the immune evasion mechanisms of dormant prostate cancer cells, providing a framework for further research and immune-based therapies.
Review
Oncology
Sepideh Mirzaei, Mahshid Deldar Abad Paskeh, Elena Okina, Mohammad Hossein Gholami, Kiavash Hushmandi, Mehrdad Hashemi, Azuma Kalu, Ali Zarrabi, Noushin Nabavi, Navid Rabiee, Esmaeel Sharifi, Hassan Karimi-Maleh, Milad Ashrafizadeh, Alan Prem Kumar, Yuzhuo Wang
Summary: This review highlights the role of epigenetic alterations in the development of prostate cancer, specifically focusing on lncRNAs. Aberrant expression of lncRNAs in prostate cancer is well-documented, affecting various molecular pathways and regulating tumor progression. Additionally, lncRNAs play a role in radio-resistance, chemo-resistance, and immune evasion of prostate cancer, making them potential targets for therapeutic interventions.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Chemistry, Multidisciplinary
Milad Ashrafizadeh, Shahin Aghamiri, Shing Cheng Tan, Ali Zarrabi, Esmaeel Sharifi, Navid Rabiee, Firoz Babu Kadumudi, Alireza Dolatshahi Pirouz, Masoud Delfi, Kullaiah Byrappa, Vijay Kumar Thakur, Kothanahally S. Sarath Kumar, Yarabahally R. Girish, Farshid Zandsalimi, Ehsan Nazarzadeh Zare, Gorka Orive, Franklin Tay, Kiavash Hushmandi, Alan Prem Kumar, Ceren Karaman, Hassan Karimi-Maleh, Ebrahim Mostafavi, Pooyan Makvandi, Yuzhuo Wang
Summary: Nanocarriers have great potential in the treatment of prostate cancer, improving the efficacy of chemotherapy and radiotherapy through targeting drug delivery and gene expression regulation, suppressing the proliferation and metastasis of PCa cells, and detecting biomarkers for PCa diagnosis.
Article
Multidisciplinary Sciences
Nader Al-Nakouzi, Chris Kedong Wang, Htoo Zarni Oo, Irina Nelepcu, Nada Lallous, Charlotte B. Spliid, Nastaran Khazamipour, Joey Lo, Sarah Truong, Colin Collins, Desmond Hui, Shaghayegh Esfandnia, Hans Adomat, Thomas Mandel Clausen, Tobias Gustavsson, Swati Choudhary, Robert Dagil, Eva Corey, Yuzhuo Wang, Anne Chauchereau, Ladan Fazli, Jeffrey D. Esko, Ali Salanti, Peter S. Nelson, Martin E. Gleave, Mads Daugaard
Summary: Inhibition of the androgen receptor pathway leads to the upregulation of chondroitin sulfate (CS), which promotes the growth and metastasis of prostate cancer.
NATURE COMMUNICATIONS
(2022)
Review
Biotechnology & Applied Microbiology
Milad Ashrafizadeh, Ali Zarrabi, Hassan Karimi-Maleh, Afshin Taheriazam, Sepideh Mirzaei, Mehrdad Hashemi, Kiavash Hushmandi, Pooyan Makvandi, Ehsan Nazarzadeh Zare, Esmaeel Sharifi, Arul Goel, Lingzhi Wang, Jun Ren, Yavuz Nuri Ertas, Alan Prem Kumar, Yuzhuo Wang, Navid Rabiee, Gautam Sethi, Zhaowu Ma
Summary: Nanomedicine has great potential in the treatment of bladder cancer, including improving drug efficacy, regulating gene expression, providing photodynamic and photothermal therapy, remodeling tumor microenvironment and infiltration of immune cells, timely diagnosis, and targeted therapy for bladder cancer.
BIOENGINEERING & TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Jonathan Chou, Emily A. Egusa, Sinan Wang, Michelle L. Badura, Fei Lee, Anil P. Bidkar, Jun Zhu, Tanushree Shenoy, Kai Trepka, Troy M. Robinson, Veronica Steri, Jiaoti Huang, Yuzhuo Wang, Eric J. Small, Emily Chan, Bradley A. Stohr, Alan Ashworth, Brant Delafontaine, Sylvie Rottey, Keegan S. Cooke, Nooshin Hashemi Sadraei, Brian Yu, Mark Salvati, Julie M. Bailis, Felix Y. Feng, Robert R. Flavell, Rahul Aggarwal
Summary: The expression of DLL3 in de novo and treatment-emergent small-cell/neuroendocrine (t-SCNC) prostate cancer is associated with reduced survival. A PET agent, [89Zr]-DFO-DLL3-scFv, has been developed to detect DLL3 levels in mouse SCNC models. The DLL3-targeted bispecific T-cell engager (BiTE) immunotherapy, AMG 757 (tarlatamab), exhibits potent and durable antitumor activity in patient-derived xenograft models.
Article
Urology & Nephrology
Mitchell G. Lawrence, Renea A. Taylor, Georgia B. Cuffe, Lisa S. Ang, Ashlee K. Clark, David L. Goode, Laura H. Porter, Clementine Le Magnen, Nora M. Navone, Jack A. Schalken, Yuzhuo Wang, Wytske M. van Weerden, Eva Corey, John T. Isaacs, Peter S. Nelson, Gail P. Risbridger
Summary: This Perspective article discusses patient-derived xenografts (PDXs) of prostate cancer and their utility in basic and preclinical research. The authors emphasize the need for more diverse and accessible PDX models to reflect patient diversity and study emerging treatment strategies and mechanisms of resistance. Collaboration and data sharing can greatly enhance the use of PDXs in prostate cancer research.
NATURE REVIEWS UROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Fan Zhang, Maitree Biswas, Shabnam Massah, Joseph Lee, Shreyas Lingadahalli, Samantha Wong, Christopher Wells, Jane Foo, Nabeel Khan, Helene Morin, Neetu Saxena, Sonia H. Y. Kung, Bei Sun, Ana Karla Parra Nunez, Christophe Sanchez, Novia Chan, Lauren Ung, Umut Berkay Altintas, Jennifer M. Bui, Yuzhuo Wang, Ladan Fazli, Htoo Zarni Oo, Paul S. Rennie, Nathan A. Lack, Artem Cherkasov, Martin E. Gleave, Jorg Gsponer, Nada Lallous
Summary: Numerous cancers, including prostate cancer (PCa), rely on transcription programs driven by specific genomic regions called super-enhancers. The androgen receptor (AR), the main oncogenic driver in PCa, forms liquid-like foci in different PCa models, and this foci formation is correlated with AR transcriptional activity. AR antagonists inhibit foci formation and phase separation of AR, suggesting that enhanced compartmentalization of AR and coactivators may play a crucial role in the activation of oncogenic transcription programs in androgen-dependent PCa.
NUCLEIC ACIDS RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Reyadh R. Al-Rashidi, Sara Abdalrazzaq M. Noraldeen, Ali Kamil Kareem, Aisha Kamal Mahmoud, Wesam R. Kadhum, Andres Alexis Ramirez-Coronel, Acim Heri Iswanto, Rasha Fadhel Obaid, Abduladheem Turki Jalil, Yasser Fakri Mustafa, Noushin Nabavi, Yuzhuo Wang, Lin Wang
Summary: Prostate carcinoma is a malignant disease caused by genomic alterations in the prostate. Dysregulation of NF-kappa B pathway promotes carcinogenesis and resistance to therapy. Research on genetic mutations and NF-kappa B function has the potential to introduce novel therapies for this incurable disease. Noncoding RNA transcripts can regulate NF-kappa B level, offering a potential avenue for modulating prostate cancer progression.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Medicine, Research & Experimental
Mu-En Wang, Jiaqi Chen, Yi Lu, Alyssa R. Bawcom, Jinjin Wu, Jianhong Ou, John M. Asara, Andrew J. Armstrong, Qianben Wang, Lei Li, Yuzhuo Wang, Jiaoti Huang, Ming Chen
Summary: Inactivation of the RB1 tumor suppressor gene is common in therapy-resistant cancers and predicts poor clinical outcomes. Loss of RB1 and activation of E2F sensitizes cancer cells to ferroptosis, and targeting this pathway with a GPX4 inhibitor inhibits tumor growth and improves survival in RB1-deficient cancers. These findings suggest a promising therapeutic approach for RB1-deficient malignancies.
JOURNAL OF CLINICAL INVESTIGATION
(2023)